This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours. Two schedules with sunitinib (25-50 mg per day) and IV gemcitabine (750-1250 mg mForty-four patients received the combination (Schedule 4/2,Sunitinib plus gemcitabine on Schedule 2/1 with growth factor support was well tolerated and safely administered at maximum doses of each drug, without significant drug-drug interactions.